Argenx
Update in progressARGX (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
argenx SE is a commercial-stage biopharma company focused on autoimmune diseases, operating in the US, Japan, China, the Netherlands, and globally. It markets VYVGART for generalized MG and ITP, and VYVGART HYTRULO for MG and CIDP. It also develops efgartigimod for several autoimmune conditions and a broad ARGX portfolio plus empasiprubart and adimanebart. Partnerships include Zai Lab, Halozyme, OncoVerity, and AbbVie. Based in Amsterdam, founded 2008.
Company score
- Sentiment
- 0.67
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.59
- Governance
- 0.16
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.21
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.44
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!